Our team conducted a review of all the biotech acquisitions of 2021 and distilled it down to the acquisitions of drug discovery-focused biotechs.
Navigate the 2021 M&A Series
- the top overall drug discovery M&A transactions by value (Part 1)
- the transactions with disclosed upfront payments (Part 2)
- the most valuable small molecule acquisitions (Part 3)
- the most valuable large molecule transactions (Part 4)
- the small molecules acquired in 2021 M&A: deep dive (Part 5)
- the large molecules acquired in 2021 M&As: deep dive (Part 6)
Here, we provide a comprehensive overview of the full series, including a PDF poster book; a complete list of the acquired lead molecules with disclosed structures that were acquired in 2021, with an accompanying deep-dive slide deck; a complete list of acquisitions of biotech companies focused on molecular drug discovery in 2021, with an accompanying deep-dive slide deck; and finally an interactive table of all the biotech acquisitions of 2021.
get free samples and a Premium trial
Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: